211 related articles for article (PubMed ID: 2338416)
1. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
Norrby SR; Burman LA; Sassella D; Corigli R; Cassinelli G; Franceschi G; Dornbusch K
J Antimicrob Chemother; 1990 Mar; 25(3):371-83. PubMed ID: 2338416
[TBL] [Abstract][Full Text] [Related]
2. Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem.
Schliamser SE; Broholm KA; Liljedahl AL; Norrby SR
J Antimicrob Chemother; 1988 Nov; 22(5):687-95. PubMed ID: 3209527
[TBL] [Abstract][Full Text] [Related]
3. Toxicological profile of FCE 22101 and its orally available ester FCE 22891.
Brughera M; Scampini G; Ferrari ML; Nava A; Mazué G
J Antimicrob Chemother; 1989 Mar; 23 Suppl C():129-35. PubMed ID: 2732134
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
Verpooten GA; Verbist L; Buntinx AP; Entwistle LA; Jones KH; De Broe ME
Br J Clin Pharmacol; 1984 Aug; 18(2):183-93. PubMed ID: 6593092
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus.
Sundelof JG; Thompson R; White KM; Sasor MW; Cama L; Kropp H
Antimicrob Agents Chemother; 1996 Mar; 40(3):795-8. PubMed ID: 8851616
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
7. Single-dose pharmacokinetics of imipenem-cilastatin in neonates.
Gruber WC; Rench MA; Garcia-Prats JA; Edwards MS; Baker CJ
Antimicrob Agents Chemother; 1985 Apr; 27(4):511-4. PubMed ID: 3859243
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of imipenem-cilastatin in neonates.
Freij BJ; McCracken GH; Olsen KD; Threlkeld N
Antimicrob Agents Chemother; 1985 Apr; 27(4):431-5. PubMed ID: 3859242
[TBL] [Abstract][Full Text] [Related]
9. An overview of the pharmacology of imipenem/cilastatin.
Drusano GL
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():79-92. PubMed ID: 3546249
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacokinetics of an imipenem-cilastatin combination].
Singlas E
Presse Med; 1990 Apr; 19(13):598-605. PubMed ID: 2139939
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of imipenem and cilastatin in volunteers.
Rogers JD; Meisinger MA; Ferber F; Calandra GB; Demetriades JL; Bland JA
Rev Infect Dis; 1985; 7 Suppl 3():S435-46. PubMed ID: 3863219
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function.
Pietroski NA; Graziani AL; Lawson LA; Bland JA; Rogers JD; MacGregor RR
Antimicrob Agents Chemother; 1991 May; 35(5):972-5. PubMed ID: 1854179
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
Alarabi AA; Cars O; Danielson BG; Salmonson T; Wikström B
J Antimicrob Chemother; 1990 Jul; 26(1):91-8. PubMed ID: 2211452
[TBL] [Abstract][Full Text] [Related]
14. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats.
Nakamura T; Hashimoto Y; Kokuryo T; Inui KI
Pharm Res; 1998 May; 15(5):734-8. PubMed ID: 9619782
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of FCE 22101 in man following different modes of administration.
Lovering AM; White LO; Lewis DA; MacGowan AP; Routh KR; Pickin DM; Reeves DS
J Antimicrob Chemother; 1989 Mar; 23 Suppl C():179-95. PubMed ID: 2732141
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891.
Lovering AM; MacGowan AP; Lewis DA; Reeves DS
J Antimicrob Chemother; 1992 Feb; 29(2):179-85. PubMed ID: 1506334
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis.
Reed MD; Stern RC; O'Brien CA; Yamashita TS; Myers CM; Blumer JL
Antimicrob Agents Chemother; 1985 Apr; 27(4):583-8. PubMed ID: 3859245
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
[TBL] [Abstract][Full Text] [Related]
20. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
Keller E; Fecht H; Böhler J; Schollmeyer P
Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
